Public source
Reviewed 3 Jun 2026
Completeness Fair (28%)
Ibex Gastric
IBEXIbex Gastric assists pathologists in the diagnosis of gastric biopsies by improving the detection and grading of cancer and other clinically important features, and enabling multiple automated decision support and reporting tools. The AI model detects 34 tissue morphologies; The aims of the software are:
• Triage with tagged case-level and slide-level AI findings
• Optimization with IHC pre-ordering based on AI findings
• Increased accuracy with AI-powered heatmaps for HG dysplasia, carcinoma & HG lymphoma
• Increased efficiency with AI-powered heatmaps for H. Pylori & gastritis
• AI-powered heatmaps IDing lymphomas, neuroendocrine neoplasm, intestinal metaplasia, adenoma & LG dysplasia
No papers to support — we monitor for new evidence.
General Information
Product name
Company
Modality
Main task
Subspeciality
Organ/Specimen source
Not specified
Disease targeted
Specimen type
Staining
Stain subtype
Not specified
Regulatory Information
Pathway:
In Vitro Diagnostic Directive (IVDD)
Class:
General IVD Devices
Not verified by Health AI Register
Scanner Brands Certified for Use (CE-IVD)
Not specified
Scanner Models Certified for Use (CE-IVD)
Not specified
Other certifications
Not specified
Evidence & Research
No research papers or evidence on file yet.
The registry monitors publications for new evidence.
Technical Specifications
Patient population age
Not specified
Input
Not specified
Input format
Not specified
Output
Not specified
Output format
Not specified
Integration
Not specified
Deployment
Not specified
Trigger for analysis
Not specified
Processing time
Not specified
Population
Not specified
Viewer systems
Not specified
Market Presence
On market since
Not specified
AI Platforms
Resellers
Not specified
Countries present
Not specified
Paying clinical customers
Not specified
Research/test users
Not specified
Pricing Information
Pricing model
Not specified
Based on
Not specified
Source: Public | First published: Aug 1, 2025 | Last updated: Jun 3, 2026